Research location
Headington
United Kingdom
Advertisement
Research activity in Headington
United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 21 trials and 21 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Headington
21 linked trials · page 1 of 1Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaNCT06435273 · 2024-08-05 · 1 site observation
COMPLETED
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · 2023-09-28 · 1 site observation
COMPLETED
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesNCT05791201 · 2023-05-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.NCT05408039 · 2022-07-14 · 1 site observation
COMPLETED
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.NCT04564742 · 2020-12-22 · 1 site observation
COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid TumorsNCT04592484 · 2020-09-15 · 1 site observation
COMPLETED
Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsNCT03953300 · 2019-10-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)NCT03688074 · 2018-11-02 · 1 site observation
COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 · 2017-06-15 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderNCT03187769 · 2017-06-08 · 1 site observation
COMPLETED
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02952534 · 2017-02-15 · 1 site observation
COMPLETED
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeNCT03000192 · 2016-08-01 · 1 site observation
UNKNOWN
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung CancerNCT02735980 · 2016-05-11 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 DiabetesNCT01885208 · 2013-12-02 · 1 site observation
COMPLETED
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT01578707 · 2012-06-01 · 1 site observation
COMPLETED
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell TransplantationNCT01206101 · 2012-03-21 · 1 site observation
TERMINATED
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 DiabetesNCT01336023 · 2011-05-23 · 1 site observation
COMPLETED
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsNCT01127750 · 2010-05-01 · 1 site observation
COMPLETED
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 DiabetesNCT01011868 · 2009-11-01 · 1 site observation
COMPLETED
Phase II Study of BI 2536 in Prostate CancerNCT00706498 · 2006-09-01 · 1 site observation
COMPLETED
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 DiabetesNCT00184600 · 2004-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.